Indivior Pharmaceuticals (INDV) Total Liabilities (2021 - 2026)

Indivior Pharmaceuticals' Total Liabilities history runs 6 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Total Liabilities fell 19.22% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (down 19.22% YoY), while the FY2025 annual figure was $1.3 billion, down 21.31% from the prior year.
• Total Liabilities was $1.3 billion for Q1 2026 at Indivior Pharmaceuticals, up from $1.3 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $1.9 billion in Q4 2023 to a low of $161.0 million in Q1 2024.
• Historically, Total Liabilities has averaged $1.2 billion across 5 years, with a median of $1.6 billion in 2025.
• Biggest YoY gain for Total Liabilities was 931.06% in 2025; the steepest drop was 21.31% in 2025.
• A 5-year view of Total Liabilities shows it stood at $1.7 billion in 2022, then climbed by 13.04% to $1.9 billion in 2023, then declined by 14.93% to $1.7 billion in 2024, then slipped by 21.31% to $1.3 billion in 2025, then climbed by 3.15% to $1.3 billion in 2026.
• The last three Total Liabilities figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.